DelveInsight’s ‘Moderate to Severe Plaque Psoriasis Pipeline Insight 2023‘ report provides comprehensive global coverage of available, marketed, and pipeline Moderate to Severe Plaque Psoriasis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Moderate to Severe Plaque Psoriasis pipeline domain.
For Moderate to Severe Plaque Psoriasis emerging drugs, the Moderate to Severe Plaque Psoriasis pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the Moderate to Severe Plaque Psoriasis Pipeline Report
- DelveInsight’s Moderate to Severe Plaque Psoriasis Pipeline analysis depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for Moderate to Severe Plaque Psoriasis treatment.
- The leading Moderate to Severe Plaque Psoriasis companies include Acrutis Biotherapeutics, AnaptysBio, Evelo Biosciences, Bristol-Myers Squibb, Jiangsu Hengrui Medicine, Akeso Biopharma, Suzhou Zelgen Biopharmaceuticals, Sun Pharmaceutical Industries Limited, GC Cell Corporation, Nimbus Therapeutics, Bioeq GmbH, Dong-A ST Co., Ltd., Can-fite biopharma, Bio-thera solutions, AbbVie, Sinocelltech, Jansen research and development, Innovent Biologics, Aurigene discovery, Affibody, GlaxoSmithKline, Abcentra, and others are evaluating their lead assets to improve the Moderate to Severe Plaque Psoriasis treatment landscape.
- Key Moderate to Severe Plaque Psoriasis pipeline therapies in various stages of development include BMS-986165, SHR 1314, Ebdarokimab, Jaktinib, SCD-044, CT 303, FYB202, DMB-3115, CF101, BAT2206, ABP 654, SCT630, SCD-044, NDI-034858, JTE-451, JNJ-77242113, IBI112, Cedirogant, AUR101, AK111, ABY-035, GSK2982772, and others.
- In January 2023, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended that Sandoz’s citrate-free high-concentration formulation (HCF) of Hyrimoz (adalimumab) biosimilar be granted marketing authorization. The company is seeking regulatory approval for Hyrimoz for several indications covered by the reference medicine, including ulcerative colitis, plaque psoriasis, rheumatoid arthritis, Crohn’s disease, and uveitis.
- In January 2023, Bristol Myers Squibb (BMS) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) had recommended Sotyktu (deucravacitinib) for moderate-to-severe plaque psoriasis.
- In December 2022, the FDA approved a resubmitted Biologics License Application (BLA) for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis.
- On April 7, 2022, Meiji Seika Pharma dosed first patient in Phase II Study of ME3183, a Selective PDE4 Inhibitor, in Patients with moderate to severe Plaque Psoriasis in the United States and Canada.
- In March 2022, Jansen Research and development announced the initiation of VISIBLE, a first-of-its-kind, large-scale prospective clinical study dedicated to people of color living with moderate to severe plaque and scalp PsO.
Request a sample and discover the recent breakthroughs happening in the Moderate to Severe Plaque Psoriasis pipeline landscape @ Moderate to Severe Plaque Psoriasis Pipeline Outlook
Moderate to Severe Plaque Psoriasis Overview
Moderate to Severe Plaque Psoriasis is the most common type of psoriasis. Plaques are thick, scaly spots that appear on the skin. Plaques psoriasis affects roughly 80% to 90% of psoriasis patients. It is an autoimmune disorder in which skin cells rapidly accumulate, resulting in scales and flaky, dry, itchy areas. Scientists do not fully comprehend the processes underlying autoimmune disorders such as Moderate to Severe Plaque Psoriasis, though genetics are thought to play a role. A third of psoriasis patients have a family history of the disease and evidence of chromosomal abnormalities in specific places of a gene (known as PSORS1 through PSORS9). Other possible causes of Moderate to Severe Plaque Psoriasis include previous infections or toxic exposure, though most of these are only speculative.
Chronic plaque psoriasis, also known as Psoriasis Vulgaris, is characterized by elevated areas of irritated skin covered with silvery-white scales. Symptoms of Moderate to Severe Plaque Psoriasis can come and go, frequently going into remission for months or even years before reappearing for no apparent reason. In other cases, plaque psoriasis symptoms may be cyclical or even seasonal. Psoriasis is incurable. The patient frequently experiences cycles in which the rash improves and then flares up again. The goal of treatment for Moderate to Severe Plaque Psoriasis is to have fewer and less severe flare-ups. Topical corticosteroids, phototherapy, vitamin D3 analogs, and retinoids are currently available as treatments for plaque psoriasis.
Find out more about Moderate to Severe Plaque Psoriasis medication @ New Drug for Moderate to Severe Plaque Psoriasis
Moderate to Severe Plaque Psoriasis Pipeline Analysis: Drug Profile
BMS-986165: Bristol-Myers Squibb
Deucravacitinib (BMS-986165) is an oral, first-in-class tyrosine kinase 2 (TYK2) inhibitor with a novel mechanism of action. Deucravacitinib is the first and only TYK2 inhibitor currently being studied in clinical trials for various immune-mediated diseases. Deucravacitinib was developed by Bristol Myers Squibb scientists to selectively target TYK2, thereby inhibiting signaling of key cytokines involved in psoriasis pathogenesis, including IL-12, IL-23, and Type 1 interferon (IFN). Bristol Myers Squibb was awarded the 2019 Thomas Alva Edison Patent Award for the science underlying the clinical development of deucravacitinib due to its innovative design. Deucravacitinib is being researched to treat various immune-mediated diseases, including psoriasis, psoriatic arthritis, lupus, and inflammatory bowel disease.
AK111: Akeso Biopharma
AK111 is a novel drug targeting IL-17A in treating autoimmune diseases developed independently by the Company. The drug AK111 is designed to treat psoriasis, ankylosing spondylitis, and axial spondylitis. AK111 has achieved clinical efficacy in immune-related diseases by combining competitive blockers, namely IL-17A and IL-17RA, and blocking the biological activities of IL-17. The drug is currently in Phase II clinical trial evaluation for the treatment of Moderate to Severe Plaque Psoriasis.
Moderate to Severe Plaque Psoriasis Pipeline Therapies and Key Companies
- BMS-986165: Bristol-Myers Squibb
- SHR 1314: Jiangsu Hengrui Medicine
- Ebdarokimab: Akeso Biopharma
- Jaktinib: Suzhou Zelgen Biopharmaceuticals
- SCD-044: Sun Pharmaceutical Industries Limited
- Orismilast: Union Therapeutics
- NDI 034858: Nimbus Therapeutics
- ME3183: Meiji Pharma
- CT 303: GC Cell Corporation
Learn more about the novel and emerging Moderate to Severe Plaque Psoriasis pipeline therapies @ Moderate to Severe Plaque Psoriasis Clinical Trials
Moderate to Severe Plaque Psoriasis Therapeutics Assessment
- By Product Type
- Monotherapy
- Combination Therapy
- By Stage
- Discovery
- Pre-Clinical
- Phase I
- Phase II
- Phase III
- Pre-registration
- By Route of Administration
-
- Oral
- Parenteral
- Subcutaneous
- Topical
- Intravitreal
- By Molecule Type
- Gene therapy
- Small molecule
- Polymers
- Peptides
- Monoclonal antibodies
Scope of the Moderate to Severe Plaque Psoriasis Pipeline Report
-
- Coverage: Global
- Key Moderate to Severe Plaque Psoriasis Companies: Acrutis Biotherapeutics, AnaptysBio, Evelo Biosciences, Bristol-Myers Squibb, Jiangsu Hengrui Medicine, Akeso Biopharma, Suzhou Zelgen Biopharmaceuticals, Sun Pharmaceutical Industries Limited, GC Cell Corporation, Nimbus Therapeutics, Bioeq GmbH, Dong-A ST Co., Ltd., Can-fite biopharma, Bio-thera solutions, AbbVie, Sinocelltech, Jansen research and development, Innovent Biologics, Aurigene discovery, Affibody, GlaxoSmithKline, Abcentra, and others.
- Key Moderate to Severe Plaque Psoriasis Pipeline Therapies: BMS-986165, SHR 1314, Ebdarokimab, Jaktinib, SCD-044, CT 303, FYB202 , DMB-3115, CF101, BAT2206, ABP 654, SCT630, SCD-044, NDI-034858, JTE-451, JNJ-77242113, IBI112, Cedirogant, AUR101, AK111, ABY-035, GSK2982772, and others.
Dive deep into rich insights for drugs used for Moderate to Severe Plaque Psoriasis treatment; visit @ Moderate to Severe Plaque Psoriasis Drugs
Table of Contents
| 1. | Introduction |
| 2. | Executive Summary |
| 3. | Moderate to Severe Plaque Psoriasis Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Moderate to Severe Plaque Psoriasis Pipeline Therapeutics |
| 6. | Moderate to Severe Plaque Psoriasis Pipeline: Late Stage Products (Phase III) |
| 7. | Moderate to Severe Plaque Psoriasis Pipeline: Late Stage Products (Phase III) |
| 8. | Moderate to Severe Plaque Psoriasis Pipeline: Mid Stage Products (Phase II) |
| 9. | Moderate to Severe Plaque Psoriasis Pipeline: Early Stage Products (Phase I) |
| 10. | Therapeutic Assessment |
| 11. | Inactive Products |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the Moderate to Severe Plaque Psoriasis therapy in the pipeline, reach out @ Moderate to Severe Plaque Psoriasis Medication
Related Reports
Moderate to Severe Plaque Psoriasis Market
Moderate to Severe Plaque Psoriasis Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Moderate to Severe Plaque Psoriasis companies involved such as Suzhou Zelgen Biopharmaceuticals, Sun Pharmaceutical Industries Limited, GC Cell Corporation, among others.
Moderate to Severe Plaque Psoriasis Epidemiology Forecast
Moderate to Severe Plaque Psoriasis Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical and forecasted Moderate to Severe Plaque Psoriasis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Plaque Psoriasis Pipeline Insight, 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Plaque Psoriasis companies involved, such as Acrutis Biotherapeutics, AnaptysBio, Evelo Biosciences, Bristol-Myers Squibb, among others.
Chronic Plaque Psoriasis Pipeline
Chronic Plaque Psoriasis Pipeline Insight, 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Chronic Plaque Psoriasis companies involved, such as Jiangsu Hengrui Medicine, Akeso Biopharma, Suzhou Zelgen Biopharmaceuticals, among others.
Plaque Psoriasis Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Plaque Psoriasis companies involved such as Suzhou Zelgen Biopharmaceuticals, Sun Pharmaceutical Industries Limited, GC Cell Corporation, among others.
Mild to Moderate Plaque Psoriasis Market
Mild to Moderate Plaque Psoriasis Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Mild to Moderate Plaque Psoriasis companies involved such as Suzhou Zelgen Biopharmaceuticals, Acrutis Biotherapeutics, AnaptysBio, Evelo Biosciences, BMS, among others.
Other Trending Reports
Goitre Market | Venous Stenosis Market | Negative Pressure Wound Therapy Systems Market | Global Kinase Inhibitor in Autoimmune Diseases Market | Metrorrhagia Market | Dysfunctional Uterine Bleeding Market | Hypereosinophilic Syndrome Market | Age-related Vision Dysfunction Market | Dental Lasers Market | CRISPR Therapies Pipeline Insight | Cell And Gene Therapy For Multiple Myeloma Market | Drug Hypersensitivity Market | Dysthymia Market | Persistent Depressive Disorder Market | Cancer Vaccines Market | Global Messenger RNA (mRNA)-based Vaccines and Therapeutics Market |Spirometers Market | Hemodynamic Monitoring Systems Market | Deep Brain Stimulation Devices Market | Genital Herpes Market | Guillain-Barre Syndrome (GBS) Market | Hot Flashes Market | Human Immunodeficiency Virus Type-1 (HIV-1) Market | Hypertrophic Scar Market | Sinus Dilation Devices Market | Artificial Cornea and Corneal Implant Market |Peripheral Neuritis Market | Peripheral Vascular Devices Market | Diphtheria Market | Glioma Market | Fallopian Tube Cancer Market | Implantable Cardioverter Defibrillators (ICDs) Market | Smart Inhalers Market | Thyroid Cancer Market | Hemostasis Market | Peptic Ulcers Market
Related Healthcare Blogs
Upcoming Drugs for Autoimmune Diseases
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect With Us at LinkedIn | Facebook | Twitter
Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187